ArticleInfectious diseases and therapy2025
Cost-Effectiveness Analysis of a Bivalent RSVPreF Vaccine in Japanese Adults Aged 60 Years and Older.
Article in Infectious diseases and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRespiratory syncytial virus (RSV) is a major cause of acute respiratory illness. A bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved in Japan to prevent RSV-related diseases in older adults in 2024. This study evaluated the cost-effectiveness of the RSVpreF vaccine compared with no vaccination in Japanese adults aged 60 years and older from the payer and societal perspectives.
methodsA population-based, multi-cohort, Markov-type model was used to estimate the economic and health impact of vaccination against RSV over a lifetime horizon. Model inputs were derived from published Japanese and international sources. Vaccine effectiveness was derived from clinical trial data and assumed to wane over time. The base-case analysis was conducted assuming a vaccination rate of 50%. Scenario analyses, along with deterministic and probabilistic sensitivity analyses, were conducted to assess the uncertainty around model inputs.
resultsThe RSVpreF vaccine was anticipated to reduce 204,145 cases of RSV hospitalization, 113,170 cases of RSV emergency department visits, 542,790 cases of RSV outpatient visits, and 27,764 RSV-related deaths versus no vaccination. These reductions in disease burden resulted in savings of Japanese yen (JPY) 176,121 million in medical expenses and JPY 161,307 million in productivity losses. There was an incremental gain of 290,312 quality-adjusted life-years (QALYs), with incremental cost-effectiveness ratios (ICERs) of JPY 1,458,898/QALY from the payer perspective and JPY 903,263/QALY from the societal perspective, which was below the cost-effectiveness threshold of JPY 5 million/QALY. The scenario and sensitivity analyses confirmed the robustness of the results.
conclusionsThe RSVpreF vaccine is cost-effective compared to no vaccination for adults aged 60 years and older in Japan. It has the potential to provide significant public health benefits by reducing the burden of RSV-related diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.